Myocardial infarction associated with erenumab: A case report.
Justine PerinoVirginie CorandElise LaurentHélène ThéophileGhada Miremont-SalaméAntoine ParienteJean-Laurent ColasThierry CouffinhalFrancesco SalvoPublished in: Pharmacotherapy (2022)
Further evidence is needed to assess the risk of myocardial infarction in patients treated with a CGRP-mab. In patients over 40 years of age, the risk of coronary or cardiovascular events should be assessed using risk tables or algorithms to take into account cardiovascular risk factors. This may be complemented by appropriate examinations to measure the burden of coronary atherosclerosis, if necessary.
Keyphrases
- cardiovascular events
- coronary artery disease
- cardiovascular risk factors
- cardiovascular disease
- coronary artery
- end stage renal disease
- heart failure
- ejection fraction
- newly diagnosed
- chronic kidney disease
- metabolic syndrome
- prognostic factors
- deep learning
- risk factors
- atrial fibrillation
- aortic valve
- patient reported